TPIDB > 臨床試驗主持人
臨床試驗主持人
更新時間：2025-03-04
余忠仁Yu, Chong-Jen
- 計畫主持人
- 執行臨床試驗年資 23 年 9 個月
發表文獻
116筆
101
Hsieh CC, Yu CJ, Chen HJ, Chen YW, Chang NT, Hsiao FH. Dispositional mindfulness, self-compassion, and compassion from others as moderators between stress and depression in caregivers of patients with lung cancer. Psychooncology. 2019 Jul;28(7):1498-1505. doi: 10.1002/pon.5106. Epub 2019 Jun 6. PMID: 31087458.
102
Chen YF, Cheng YC, Chou CH, Chen CY, Yu CJ. Major comorbidities lead to the risk of adverse cardiovascular events in chronic obstructive pulmonary disease patients using inhaled long-acting bronchodilators: a case-control study. BMC Pulm Med. 2019 Dec 3;19(1):233. doi: 10.1186/s12890-019-0999-z. PMID: 31795986; PMCID: PMC6889444.
103
Chen YH, Chen YF, Chen CY, Shih JY, Yu CJ. Clinical factors associated with treatment outcomes in EGFR mutant non-small cell lung cancer patients with brain metastases: a case-control observational study. BMC Cancer. 2019 Oct 26;19(1):1006. doi: 10.1186/s12885-019-6140-0. PMID: 31655564; PMCID: PMC6815404.
104
Wu JY, Yu CJ, Shih JY. Effectiveness of Treatments for Advanced Non-Small-Cell Lung Cancer With Exon 20 Insertion Epidermal Growth Factor Receptor Mutations. Clin Lung Cancer. 2019 Nov;20(6):e620-e630. doi: 10.1016/j.cllc.2019.06.018. Epub 2019 Jun 26. PMID: 31327643.
105
Lin YT, Chen JS, Liao WY, Ho CC, Hsu CL, Yang CY, Chen KY, Lee JH, Lin ZZ, Shih JY, Yang JC, Yu CJ. Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first-line gefitinib, erlotinib and afatinib-treated non-small cell lung cancer patients with activating EGFR mutations. Int J Cancer. 2019 Jun 1;144(11):2887-2896. doi: 10.1002/ijc.32025. Epub 2019 Jan 5. PMID: 30485437.
106
Lin CA, Yu SL, Chen HY, Chen HW, Lin SU, Chang CC, Yu CJ, Yang PC, Ho CC. EGFR-Mutant SCLC Exhibits Heterogeneous Phenotypes and Resistance to Common Antineoplastic Drugs. J Thorac Oncol. 2019 Mar;14(3):513-526. doi: 10.1016/j.jtho.2018.11.021. Epub 2018 Dec 3. PMID: 30521971.
107
Chen LC, Shih JY, Yu CJ, Yang CY. A rare epidermal growth factor receptor H773L/V774M compound mutation in advanced non-small-cell lung cancer with poor response to epidermal growth factor receptor tyrosine kinase inhibitor. Respirol Case Rep. 2019 Apr 10;7(5):e00425. doi: 10.1002/rcr2.425. PMID: 31007929; PMCID: PMC6456914.
108
Socinski MA, Jotte RM, Cappuzzo F, Orlandi F, Stroyakovskiy D, Nogami N, Rodríguez-Abreu D, Moro-Sibilot D, Thomas CA, Barlesi F, Finley G, Kelsch C, Lee A, Coleman S, Deng Y, Shen Y, Kowanetz M, Lopez-Chavez A, Sandler A, Reck M; IMpower150 Study Group. Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC. N Engl J Med. 2018;378:2288-2301.
109
Soria JC, Tan D, Chiari R, Wu YL, Paz-Ares L, Wolf J, Geater SL, Orlov S, Cortinovis D, Yu CJ, Hochmair M, Cortot AB, Tsai CM, Moro-Sibilot D, Campelo RG, McCulloch T, Sen P, Dugan M, Pantano S, Branle F, Massacesi C, de Castro Jr G. First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non–small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study. Lancet 2017;389:917-929.
110
Wedzicha JA, Banerji D, Chapman KR, Vestbo J, Roche N, Ayers RT, Thach C, Fogel R, Patalano F, Vogelmeier CF; FLAME Investigators. Indacaterol- Glycopyrronium versus Salmeterol-Fluticasone for COPD. N Engl J Med. 2016;374: 2222-34.
